Gilead Sciences (WBO:GILD) Change In Payables And Accrued Expense : €92 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Change In Payables And Accrued Expense?

Gilead Sciences's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €251 Mil. It means Gilead Sciences's Accounts Payable & Accrued Expense increased by €251 Mil from Sep. 2023 to Dec. 2023 .

Gilead Sciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €102 Mil. It means Gilead Sciences's Accounts Payable & Accrued Expense increased by €102 Mil from Dec. 2022 to Dec. 2023 .

Gilead Sciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Gilead Sciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Change In Payables And Accrued Expense Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-160.20

-47.68

505.34

-518.26

101.79

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															585.28	-761.21	582.41	19.68	251.26

Gilead Sciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €92 Mil.

Gilead Sciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (WBO:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.